Talphera (TLPH) Q2 FY26 earnings call

Talphera is advancing its lead asset, Nefamistat, with the NEFRO CRRT study reaching 75% enrollment and on track for completion this year. Recent inclusion in the KDIGO guidelines and updated market research indicating a larger addressable market for Nefamistat, if approved, bolster commercialization prospects. The company is preparing for a potential launch post-PMA submission, leveraging a targeted rollout strategy.